Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
NCT03605927Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2019
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of letolizumab in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Moffitt Cancer Center. Primary endpoint: Incidence of Grade II-IV Acute Graft-versus Host Disease at 1 year. Started Feb 2019; status: completed.
02
Drugs
letolizumab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT03605927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03605927.